HTFL HEARTFLOW INC

Heartflow to Participate in the Piper Sandler 37th Annual Healthcare Conference

Heartflow to Participate in the Piper Sandler 37th Annual Healthcare Conference

MOUNTAIN VIEW, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in artificial intelligence (AI) technology for coronary artery disease (CAD), today announced that members of management will participate in a fireside chat at the upcoming Piper Sandler 37th Annual Healthcare Conference. The fireside chat will take place on Wednesday, December 3, 2025, at 12:30 p.m. PT / 3:30 p.m. ET.

A live and archived version of the fireside chat will be available on the Investor Relations section of the Heartflow website at .

About Heartflow’s Technology and Research

Heartflow’s technology is redefining precision cardiovascular care through clinically-proven AI and the world’s largest coronary imaging dataset. Heartflow has been adopted by more than 1,400 institutions globally and continues to strengthen its commercial presence to make this cutting-edge solution more widely available to an increasingly diverse patient population. Backed by American College of Cardiology and American Heart Association (ACC/AHA) guidelines and supported by more than 600 peer-reviewed publications, Heartflow has redefined how clinicians manage care for over 500,000 patients worldwide. Key benefits include:

  • Proprietary data pipeline: Built from more than 110 million annotated CTA images, Heartflow’s data foundation powers advanced AI models that deliver highly accurate, reproducible insights across diverse patient populations.
  • Extensive clinical and real-world validation: Heartflow’s AI-driven solutions have been validated through clinical evidence in over 100 studies assessing over 365,000 patients. Proven in real-world practice with reproducibility and accuracy, Heartflow’s coronary CTA image acceptance rates exceed 96%.
  • Seamless clinical integration via upgraded workflow: Heartflow delivers final quality-reviewed analyses instantly upon order, enabling clinicians to move from diagnosis to decision without delay.
  • Quality system, global security and patient-data integrity compliance: Heartflow meets or exceeds leading international standards, including HITRUST, SOC 2 Type 2, ISO 13485, and ISO 27001.

About Heartflow, Inc.

Heartflow is transforming coronary artery disease from the world’s leading cause of death into a condition that can be detected early, diagnosed accurately, and managed for life. The  platform uses AI to turn coronary CTA images into personalized 3D models of the heart, providing clinically meaningful, actionable insights into plaque location, volume, and composition and its effect on blood flow — all without invasive procedures. Discover how we’re shaping the future of cardiovascular care at .

Investor Contact

Nick Laudico

Media Contact

Elliot Levy



EN
19/11/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on HEARTFLOW INC

 PRESS RELEASE

Heartflow to Participate in the Piper Sandler 37th Annual Healthcare C...

Heartflow to Participate in the Piper Sandler 37th Annual Healthcare Conference MOUNTAIN VIEW, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in artificial intelligence (AI) technology for coronary artery disease (CAD), today announced that members of management will participate in a fireside chat at the upcoming Piper Sandler 37th Annual Healthcare Conference. The fireside chat will take place on Wednesday, December 3, 2025, at 12:30 p.m. PT / 3:30 p.m. ET. A live and archived version of the fireside chat will be available on the Investo...

 PRESS RELEASE

Heartflow Reports Third Quarter 2025 Financial Results

Heartflow Reports Third Quarter 2025 Financial Results Initiates Full Year 2025 Revenue Guidance of $173.0 Million to $173.5 Million MOUNTAIN VIEW, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in artificial intelligence (AI) technology for coronary artery disease (CAD), today reported financial results for the three months ended September 30, 2025. Third Quarter 2025 Highlights Total revenue of $46.3 million, a 41% increase year-over-yearGross margin of 76.5%, non-GAAP gross margin of 76.8%Net operating loss of $15.1 million, non-GAA...

 PRESS RELEASE

AHA 2025: Late-Breaking Data Reinforce the Prognostic Power of AI-Driv...

AHA 2025: Late-Breaking Data Reinforce the Prognostic Power of AI-Driven Heartflow Plaque Analysis as the Most Clinically Validated Framework for Coronary Risk Stratification Multicenter outcomes FISH&CHIPS study of nearly 8,000 patients confirms total plaque volume as a powerful independent predictor of long-term cardiovascular events NEW ORLEANS, Nov. 09, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced late-breaking data from the FISH&CHIPS Study presented at the American Heart Associat...

 PRESS RELEASE

Heartflow to Present Late-Breaking Data Advancing AI-Driven Heartflow ...

Heartflow to Present Late-Breaking Data Advancing AI-Driven Heartflow Plaque Analysis at AHA 2025 Data to highlight the precision of AI-powered Heartflow Plaque Staging framework in predicting long-term cardiovascular outcomes MOUNTAIN VIEW, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will present new late-breaking data highlighting the clinical and economic value of Heartflow Plaque Analysis at the American Heart Association (AHA) Scientific Sessions 2025, taking ...

 PRESS RELEASE

Heartflow to Report Third Quarter 2025 Financial Results on November 1...

Heartflow to Report Third Quarter 2025 Financial Results on November 12, 2025 MOUNTAIN VIEW, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for the third quarter of 2025 after market close on Wednesday, November 12, 2025. Management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on November 12, 2025. Those interested in listening to the conference call should . Once registered, participan...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch